Clinical Pathophysiology and Evidence-Based Management of Delirium Tremens in the Hospitalized Patient cover art

Clinical Pathophysiology and Evidence-Based Management of Delirium Tremens in the Hospitalized Patient

Clinical Pathophysiology and Evidence-Based Management of Delirium Tremens in the Hospitalized Patient

Listen for free

View show details

About this listen

 In this episode of Hospital Medicine Unplugged, we sprint through delirium tremens—the most dangerous stage of alcohol withdrawal—recognize the neurochemical storm, identify high-risk patients, and treat aggressively with benzodiazepines and supportive care to prevent fatal complications. We begin with epidemiology and why DTs matter. Delirium tremens occurs in 3–5% of hospitalized patients with alcohol withdrawal and represents the most severe manifestation of the withdrawal spectrum. The syndrome combines acute delirium—rapidly fluctuating attention and cognition—with severe autonomic hyperactivity. Historically mortality approached 15%, but with modern aggressive treatment it has fallen to about 1–4%. When death occurs, it is usually due to hyperthermia, malignant arrhythmias, withdrawal seizures, or underlying medical illness. Next comes the neurobiology driving withdrawal. Chronic alcohol exposure forces the brain to compensate for alcohol’s depressant effects. Over time: • NMDA glutamate receptors are upregulated • GABA-A inhibitory receptors are downregulated While alcohol is present, its GABA-enhancing and NMDA-suppressing effects maintain balance. When alcohol is abruptly stopped, that balance collapses. The result is unopposed excitatory neurotransmission, increased glutamate signaling, reduced GABA inhibition, and massive central nervous system hyperexcitability. Additional contributors include increased norepinephrine activity, dopaminergic alterations, and calcium-mediated excitotoxicity, producing the agitation, tremor, and seizure risk characteristic of severe withdrawal. Risk stratification is essential because not every patient with withdrawal develops delirium tremens. The strongest predictor is a prior history of DTs, which carries a likelihood ratio of roughly 2.9 for recurrence. Other important risk factors include: • Recent withdrawal seizures, especially multiple seizures • High CIWA-Ar scores (>15) with tachycardia or hypertension • Older age (≥55 years) • Concurrent illness such as infection, trauma, electrolyte abnormalities, or liver disease • Hypokalemia and metabolic derangements Another key concept is the kindling effect. Repeated withdrawal episodes progressively sensitize neuronal circuits, meaning each withdrawal episode tends to become more severe than the last. The timeline of alcohol withdrawal follows a predictable pattern. • 6–12 hours: early withdrawal—tremor, anxiety, tachycardia • 12–24 hours: alcoholic hallucinosis (visual or auditory hallucinations) • 12–48 hours: withdrawal seizures • 72–96 hours: onset of delirium tremens, typically lasting 2–3 days but up to a week Importantly, about one-third of untreated withdrawal seizures progress to delirium tremens, making early treatment critical. Clinically, DTs presents with severe agitation and delirium combined with autonomic instability. Key features include: • Fluctuating confusion and disorientation • Marked agitation and psychomotor hyperactivity • Tachycardia, hypertension, fever, and diaphoresis • Coarse tremor and hyperreflexia • Vivid visual hallucinations, often insects or animals Diagnosis is clinical—delirium occurring in the context of alcohol withdrawal. The CIWA-Ar scale helps quantify withdrawal severity, but it becomes less reliable once patients develop delirium because it depends on patient responses. In ICU settings, clinicians often switch to CAM-ICU, RASS, MINDS, or DDS scales. Laboratory evaluation should focus on complications and reversible triggers. Important tests include: • Electrolytes (magnesium, potassium, phosphate) • Glucose • Liver function tests • Creatine kinase for rhabdomyolysis risk Neuroimaging should be obtained if the presentation is atypical or focal neurologic deficits are present. Management centers on rapid sedation and physiologic stabilization. Benzodiazepines are first-line therapy, acting as GABA-A agonists to counter the hyperexcitable brain. Two dosing strategies dominate: • Symptom-triggered therapy, which reduces medication exposure and treatment duration • Front-loading with high doses for severe withdrawal (CIWA-Ar ≥19) Clinicians should not fear very high benzodiazepine doses. Severe DTs may require hundreds of milligrams of diazepam per day, and case reports describe successful treatment with 260–480 mg/day. Agent selection depends on clinical context: • Diazepam or chlordiazepoxide – preferred long-acting agents for front-loading • Lorazepam – preferred in liver disease, since it lacks active metabolites For benzodiazepine-refractory DTs, ICU-level therapies may be required. Adjunctive options include: • Phenobarbital, which enhances GABA signaling and may reduce mechanical ventilation risk • Propofol, used in intubated patients with refractory agitation • Dexmedetomidine, an α2-agonist that suppresses sympathetic overactivity while allowing arousable sedation ...
No reviews yet
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.